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Purpose: The Radiation Therapy Oncology Group (RTOG) multi-institutional Phase II study 
98-12, evaluating paclitaxel and concurrent radiation (RT) for locally advanced  pancreatic  cancer, 
demonstrated a median survival of 11.3 months and a 1-year survival of 43%. The  purpose of 
the randomized Phase II study by RTOG 0020 was to evaluate the addition of weekly  low-dose 
gemcitabine with concurrent paclitaxel/RT and to evaluate the efficacy and safety of the farnesyl 
transferase inhibitor R115777 following chemoradiation.
Patients and methods: Patients with unresectable, nonmetastatic adenocarcinoma of 
the pancreas were eligible. Patients in Arm 1 received gemcitabine, 75 mg/m2/week, and 
paclitaxel, 40 mg/m2/week, for 6 weeks, with 50.4 Gy radiation (CXRT). Patients in Arm 
2 received an identical chemoradiation regimen but then received maintenance R115777, 
300 mg twice a day for 21 days every 28 days (CXRT+R115777), until disease progression 
or unacceptable toxicity.
Results: One hundred ninety-five patients were entered into this study, and 184 were analyzable. 
Grade 4 nonhematologic toxicities occurred in less than 5% of CXRT patients. The most common 
grade 3/4 toxicity from R115777 was myelosuppression; however, grade 3/4 hepatic, metabolic, 
musculoskeletal, and neurologic toxicities were also reported. The median survival time was 
11.5 months and 8.9 months for the CXRT and CXRT+R115777 arms, respectively.
Conclusions: The CXRT arm achieved a median survival of almost 1-year, supporting 
chemoradiation as an important therapeutic modality for locally advanced pancreatic cancer. 
Maintenance R115777 is not effective and is associated with a broad range of toxicities. These 
findings provide clinical evidence that inhibition of farnesylation affects many metabolic 
pathways, underscoring the challenge of developing an effective K-ras inhibitor.
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Introduction
The optimal treatment for locally advanced pancreatic cancer is controversial. 
 Chemoradiation is a standard treatment.1 However, since systemic progression is 
common, it has been suggested that the focus of treatment should be with full-dose 
systemic chemotherapy.2 This controversy may intensify with the development of a 
more effective combination chemotherapy such as FOLFIRINOX, which is comprised 
of oxaliplatin, irinotecan, fluorouracil, and leucovorin.3
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
161
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S33560
OncoTargets and Therapy 2012:5
A continuous 5-fluorouracil (5-FU) infusion or  capecitabine 
represent the most commonly utilized chemoradiation 
regimens.4–6 The Brown University Oncology Group developed 
paclitaxel as a radiation sensitizer for pancreatic cancer in 
Phase I/II studies.7–9 The Radiation Therapy Oncology Group 
(RTOG) conducted a multi-institutional Phase II study (RTOG 
98-12) with paclitaxel and concurrent radiation for 110 patients 
that resulted in a median survival of 11.3 months and a 1-year 
survival of 43%.10 Gemcitabine is now widely accepted as 
one of the most active single agents for pancreatic cancer, 
and it is a powerful radiation sensitizer.11–13 Based on a Brown 
University Oncology Group Phase I study,14 the RTOG sought 
to investigate the regimen of low-dose weekly gemcitabine, 
paclitaxel, and radiation.
The RTOG hypothesized that if chemoradiation were 
effective in controlling locoregional disease, then a biologic 
agent that could interfere with the growth and development 
of distant metastases would be beneficial in the maintenance 
setting after chemoradiation.
K-ras mutations are demonstrated in approximately 
70%–80% of pancreatic cancers.15 Farnesylation is a critical 
step in the membrane anchorage of ras proteins, required 
for ras activity. R115777 competitively inhibits the enzyme 
farnesyl protein transferase, which adds a 15-carbon farnesyl 
isoprenoid moiety to the cysteine residue of ras proteins. 
At the time this study was initiated, the inhibition of ras by 
blocking farnesyl transferase was a promising strategy in 
pancreatic cancer.16
The RTOG therefore initiated a randomized Phase II 
study to evaluate if the addition of gemcitabine radiosensi-
tization improved survival, compared to RTOG 98-12, and 
to study whether the addition of maintenance R115777 could 
delay the development of distant metastases. This is the final 
report of the multi-institutional RTOG 0020 protocol.
Materials and methods
Eligibility
All patients had pathologically confirmed, unresectable, 
nonmetastatic adenocarcinoma of the pancreas deemed unre-
sectable by extrapancreatic involvement, extensive peripan-
creatic lymphatic involvement, nodal involvement beyond the 
peripancreatic tissue, or encasement or direct invasion of the 
superior mesenteric vein, artery, inferior vena cava, aorta, or 
celiac plexus. Ineligible were those with metastatic disease to 
distant organs, ascites, or peritoneal implants and those who 
had received prior irradiation to the planned field or prior che-
motherapy including gemcitabine or paclitaxel. Patients with 
biliary or gastroduodenal obstruction had drainage prior to 
chemoradiation. All malignant disease had to be encompass-
able within an irradiation field no greater than 15 cm × 15 cm. 
Patients were not permitted to have a malignancy within 
the past 2 years, except for nonmelanoma skin cancer or 
carcinoma in situ of the cervix, uterus, or bladder. Patients 
were to have radiographically assessable disease, a Zubrod 
performance status of 0 or 1, and have no significant infection 
or other coexistent uncontrolled medical condition.
Evaluation prior to treatment
A complete history and physical examination were performed 
on all patients before treatment. Height, weight, performance 
status, and tumor stage were recorded. Required staging 
studies included a chest radiograph and an abdominal com-
puted tomographic scan. Patients were required to have the 
following laboratory values: granulocytes at $1800/µL, 
platelets at $100,000 µL, bilirubin at ,2.0 mg/dL, alanine 
aminotransferase at ,3 times upper limit of normal, and 
creatine at ,3.0 mg/dL. The study was approved by the 
institutional review boards of all participating hospitals and 
complied with the tenets of the Declaration of Helsinki. All 
patients gave written informed consent according to federal 
and institutional guidelines.
Treatment
The structure of the protocol is illustrated in the treatment 
schema in Figure 1. Radiation therapy was delivered to the 
primary tumor and draining lymph nodes over 5.5 weeks 
with coplanar anterior-posterior and lateral ports using 
a $10 MV linear accelerator. The initial fields included the 
primary tumor plus the regional peripancreatic, celiac, and 
porta hepatis lymph nodes. A conedown field was used for 
the last three fractions to encompass the gross tumor volume 
with a 1–1.5 cm margin. Computed tomographic scans in the 
treatment position were used to identify appropriate anatomy. 
When available, three-dimensional treatment planning was 
performed. The spinal cord dose was maintained below 45 Gy. 
No more than 30% of the total kidney volume received 50% 
of the prescribed dose. Concurrent systemic chemotherapy 
included paclitaxel, 40 mg/m2, and gemcitabine, 75 mg/m2, 
weekly for 6 weeks, then R115777, 300 mg, twice a day for 
21 days of a 28-day cycle, 3 to 8 weeks after completion of 
concurrent therapy.
Quality assurance
Radiotherapy quality assurance for this study included the 
central review of all diagnostic imaging and simulation 
films regarding field size, placement, tumor and lymph node 
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margin coverage, and isodose distributions. Compliance with 
chemotherapy parameters was also evaluated.
Statistics
The primary endpoint of this protocol was to determine the 
1-year survival rates of patients treated with paclitaxel, gem-
citabine, and radiation with or without R115777. Secondary 
endpoints were to determine the toxicity and locoregional 
activity of paclitaxel, gemcitabine, and radiation, to deter-
mine the feasibility and toxicity of prolonged administration 
of R115777 after paclitaxel, gemcitabine, and radiation, and 
to evaluate whether R115777 could increase progression-
free and overall survival after chemoradiation for locally 
advanced pancreatic cancer.
In the previous RTOG 98-12 protocol for unresectable 
pancreatic cancer, a 1-year survival rate of approximately 
50% was observed. Using the method of Dixon and Simon,17 
a sample size of 69 analyzable patients per arm followed over 
12 months would ensure at least 80% probability of detect-
ing a minimum of 15% improvement in the 1-year survival 
rate, compared to RTOG 98-12, at the 0.05 significance level 
(with a one-sided test). Adjusting this figure by 10% to allow 
for patient ineligibility or loss, a total sample size of at least 
154 patients was required for this study. A secondary endpoint 
of this study was to estimate the difference in 1-year survival 
for the two treatment arms. Assuming a binomial  distribution, 
the difference could be estimated with a 95% confidence 
interval (CI) with a margin of error of #17.2%.
Chi-squared tests were used to compare pretreatment 
characteristics between the treatment arms and historical 
control (RTOG 98-12). Overall and progression-free survival 
were estimated univariately with the Kaplan–Meier method,18 
and treatment arms were compared using the log-rank test. 
Reported median survival and progression-free survival 
times were the times (in years) at which 50% of the patients 
had failed the respective endpoint.  Multivariate analyses 
were performed with Cox proportional hazard models19 to 
test for treatment differences while adjusting for unbalanced 
pretreatment characteristics or time-dependent covariates. 
 Multivariate analyses were done such that a hazard ratio 
greater than 1 implied an increased risk for the second level 
of the variable and a hazard ratio less than 1 implied an 
increased risk for the first level of the variable. All analyses 
were performed using SAS software (version 9.2; SAS 
Institute, Cary, NC).
Results
Patients
One hundred ninety-five patients from 71 institutions 
were enrolled in this study between October 2001 and 
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Figure 1 Overall survival.
Abbreviations: CXRT, concurrent radiation with gemcitabine and paclitaxel; RTOG 98-12, Radiation Therapy Oncology Group study 98-12.
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December 2003. There were 185 analyzable patients for this 
report: 91 on the CXRT arm and 94 on the CXRT+R115777 
arm. Six patients were ineligible; eligibility could not be 
 confirmed for one patient, and three received no protocol 
therapy. Pretreatment characteristics for the two arms of 
RTOG 0020 are shown in Table 1 and compared to the historic 
control from RTOG 98-12.
The pretreatment characteristics were well balanced 
between the CXRT and CXRT+R115777 arms. Compared to 
RTOG 98-12, the RTOG 0020 CXRT arm had significantly 
more node-positive patients and a trend toward more higher-
tumor stage patients than had RTOG 98-12 (P = 0.04 and 
P = 0.08, respectively), while there was a trend toward more 
females (P = 0.10) in RTOG 98-12. These differences were 
not seen in the CXRT+R115777 arm and RTOG 98-12 
 comparison. RTOG 98-12 had a statistically better Zubrod 
performance status than either Arm 1 or Arm 2 of RTOG 0020 
(P = 0.0001 vs CXRT and P = 0.013 vs CXRT+R115777, 
respectively).
Quality assurance review of the radio- and chemotherapy 
treatment showed that 93% and 95%, and 87% and 87%, on 
the CXRT and CXRT+R115777 arms, respectively, were 
scored as per protocol or with acceptable variation.
Survival
All RTOG 0020 patients included in this analysis have died. 
For RTOG 0020, the median survival time was 11.5 months 
(95% CI: 8.2–12.6) for the CXRT arm and 8.9 months 
Table 1 Pretreatment characteristics of CXRT and CXRT+R115777 vs RTOG 98-12
Characteristics RTOG 98-12 
(n = 105)
CXRT 
(n = 91)
P-valuea CXRT+R115777 
(n = 94)
P-valuea
Number % Number % Number %
Age, years
 Median 63 62 - 60 -
 Min–max 29–84 40–82 43–82
Sex
 Male 50 48 54 59 0.10 52 55 0.28
 Female 55 52 37 41 42 45
Zubrod
 0 62 59 29 32 0.0001 39 41 0.013
 1 43 41 62 68 55 59
Weight loss (last 6 months)
 None n/a n/a 4 4 - 5 5 -
 #10% n/a n/a 30 33 33 35
 .10% n/a n/a 57 63 56 60
T-stage
 T1 3 3 0 0 -b 2 2 -b
 T2 16 15 10 11 14 15
 T3 48 46 17 19 12 13
 T4 36 34 64 70 66 70
 Tx 2 2 0 0 0 0
T-stage, dichotomized
 T1, T2, TX 21 20 10 11 0.08 16 17 0.59
 T3, T4 84 80 81 89 78 83
N-stage
 N0 70 67 46 51 0.04 59 63 0.61
 N1 24 23 36 40 27 29
 Nx 11 10 9 10 8 9
N-stage, dichotomized
 N0, NX 81 77 55 60 0.01 67 71 0.34
 N1 24 23 36 40 27 29
Maximum tumor size, cm
 Not measurable n/a n/a 2 2 - 5 5 -
 ,5 cm n/a n/a 62 68 54 57
 $5 cm n/a n/a 27 30 35 37
Notes: aFrom Chi-square test compared to RTOG 98-12; bChi-square test not valid.
Abbreviations: CXRT, concurrent radiation with gemcitabine and paclitaxel; RTOG 98-12, Radiation Therapy Oncology Group study 98-12; R115777, farnesyl transferase 
inhibitor; n/a, not applicable.
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(95% CI: 7.3–10.4) for the CXRT+R115777 arm. The 
cause of death was pancreas cancer-related in 90% and 93% 
of the patients on the CXRT and CXRT+R115777 arms, 
 respectively. The respective estimated 1-year survival results 
for the CXRT and the CXRT+R115777 arms were 46.2% 
(95% CI: 35.7%–56.0%, respectively for Arms 1 and 2) and 
34.0% (95% CI: 24.7%–43.6%, respectively), as compared 
to 45.3% (95% CI: 35.6%–54.5%) for RTOG 98-12.
Tables 2 and 3 show univariate and multivariate overall 
survival for RTOG 0020 and RTOG 98-12. Comparing sur-
vival between each arm of RTOG 0020 to patients treated 
on RTOG 98-12, neither regimen of RTOG 0020 was 
statistically superior (one-sided log-rank test: RTOG 0020 
CXRT vs 98-12, P = 0.15; RTOG 0020 CXRT+R115777 vs 
98-12, P . 0.99) to the historical control (Figures 2 and 3). 
Given the imbalance of sex, Zubrod, N-stage, and T-stage 
between RTOG 98-12 and the CXRT arm on RTOG 0020, 
and the imbalance of Zubrod between RTOG 98-12 and 
the CXRT+R115777 arm on RTOG 0020, multivariate 
analyses using a backward selection procedure were per-
formed to evaluate treatment differences after adjusting 
for these unbalanced variables. After adjusting for the 
above-mentioned variables, overall survival was still not 
 significantly improved for the CXRT arm, as compared to 
98-12. However, the hazard ratio indicated worse survival 
for the CXRT+R115777 arm.
Toxicity
Table 4 displays drug and acute radiotherapy toxici-
ties in Arm 1 (CXRT) and Arm 2 (CXRT+R115777). 
Multiple toxicities are scored as separate events. In the group 
receiving chemoradiation alone, Grade 3/4 hematologic 
toxicity occurred in one-third of patients. However, grade 
4 hematologic toxicity developed in only 4 of 91 patients 
(4%). Neutropenic fever developed in 5% of patients treated 
with CXRT. Grade 3 gastrointestinal toxicities, consisting 
mainly of nausea, vomiting, diarrhea, and dehydration, 
occurred in one-third of patients. However, only 2% had 
grade 4 gastrointestinal toxicities. There were no grade 5 
treatment-related events.
In contrast, Arm 2, which utilized maintenance R115777 
after chemoradiation, was associated with grade 4 myelo-
suppression in 11% of patients. Grade 3/4 nonhematologic 
toxicities in the patients receiving maintenance R115777, 
as compared to no maintenance treatment, included fatigue 
(12 vs 6 patients), increase in alanine aminotransferase 
(15 patients vs 1 patient), hypocalcemia (3 vs 0 patients), 
hyperglycemia (7 vs 0 patients), hypermagnesemia 
(1 patient vs 0 patients), muscle weakness (1 patient 
vs 0 patients),  myositis (1 patient vs 0 patients), ataxia 
(2 vs 0 patients), peripheral neuropathy (2 vs 0 patients), 
confusion (2 vs 0 patients), and myalgia (1 vs 0 patients). 
Table 5 shows late radiotherapy toxicities.
Discussion
Improving the outcome of chemosensitized external 
beam irradiation for unresectable cancer of the pancreas 
has been a goal of national protocols for the past decade; 
RTOG study 98-1210,20 evaluated paclitaxel and concur-
rent radiation without postchemoradiation gemcitabine. 
Table 2 Overall survival comparisons
Year CXRT CXRT+R115777 RTOG 98-12
% alive 
(95% CI)
Cumulative 
deaths
Number 
at risk
% alive 
(95% CI)
Cumulative 
deaths
Number 
at risk
% alive 
(95% CI)
Cumulative 
deaths
Number 
at risk
0 100.0 0 91 100.0 0 94 100.0 0 105
0.5 76.9 
(66.8, 84.3)
21 70 71.3 
(61.0, 79.3)
27 67 80.0 
(71.0, 86.5)
21 83
1.0 46.2 
(35.7, 56.0)
49 42 34.0 
(24.7, 43.6)
62 32 45.3 
(35.6, 54.5)
57 47
1.5 18.7 
(11.5, 27.3)
74 17 13.8 
(7.8, 21.6)
81 13 22.2 
(14.8, 30.5)
81 23
2.0 11.0 
(5.6, 18.4)
81 10 4.3 
(1.4, 9.7)
80 4 14.5 
(8.5, 21.9)
89 14
Total deaths 91 94 98
 MST 11.5 mos 8.9 mos 11.3 mos
 95% CI (8.2, 12.6) (7.3, 10.4) (10.2, 12.6)
Notes: Treatment comparisons vs historical control (one-sided log-rank test; RTOG 0020 testing better than RTOG 98-12 testing): CXRT vs RTOG 98-12, P = 0.1496; 
CXRT+R115777 vs RTOG 98-12, P . 0.99.
Abbreviations: CI, confidence interval; CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; MST, median survival time; 
mos, months; RTOG 0020 and 98-12, Radiation Therapy Oncology Group studies 0020 and 98-12.
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This study added low-dose gemcitabine as an additional 
radiation sensitizer.
Paclitaxel is thought to be a synchronizer of cells at G2/M, 
a relatively radiosensitive phase of the cell cycle.8,20–23 In vitro 
studies suggest that paclitaxel enhances the cytotoxicity of 
radiation even in cancer cells resistant to paclitaxel as a single 
agent,4 whereas stem cells of the gastrointestinal mucosa are 
not substantially radiosensitized by paclitaxel.22
A critical event in gemcitabine-mediated radiosensi-
tization is the inhibition of ribonucleotide reductase by 
one of its metabolites, difluorodeoxycytidine diphosphate, 
which in turn leads to depletion of deoxyadenosine triphos-
phate pools.24 The greatest radiosensitization effect is noticed 
in S-phase cells. Additional effects may be the result of the 
lowering of the threshold for radiation-induced apoptosis by 
gemcitabine.24 These differing and potentially complemen-
tary pathways of radiation sensitization by these two agents 
provide an attractive rationale for clinical testing.
Phase I/II studies of gemcitabine plus concurrent 
radiation showed the maximum tolerated dosage to depend 
on the gemcitabine dose, schedule, and volume of the 
radiation field.11 For example, Hoffman et al13 escalated 
gemcitabine from 300 mg/m2/week to 600 g/m2/week for 
6 weeks, with concurrent radiation of 50.4 Gy in patients 
with potentially resectable pancreatic cancer, irradiat-
ing only the tumor, not nodal drainage areas. In contrast, 
Table 3 Multivariate analyses of overall survival
Covariate Adjusted hazard ratioa 95% CI P-valueb
Model for RTOG 0020 CXRT and 98-12
Treatment (0 = 98-12, 1 = 0020 CXRT) 1.13 (0.85, 1.51) 0.15c
Treatment stage (0 = T1–2, Tx, 1 = T3–4) 1.64 (1.09, 2.46) 0.02
Model for RTOG 0020 CXRT+R115777 and 98-12
Treatment (0 = 98-12, 1 = 0020 CXRT+R115777) 1.54 (1.16, 2.06) .0.99c
Notes: aHazard ratio: an HR . 1 indicates an increased risk for the second level of the variable; bP-value from Cox proportional hazards model; cone-sided test per statistical 
design, testing RTOG 0020 better than RTOG 98-12.
Abbreviations: CI, confidence interval; CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; RTOG 0020 and 98-12, 
Radiation Therapy Oncology Group studies 0020 and 98-12.
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Figure 2 Overall survival comparison of RTOG 98-12 and experimental arm of RTOG 020 (online).
Abbreviations: CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; RTOG 98-12, Radiation Therapy Oncology Group 
study 98-12.
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 Blackstock et al12  demonstrated that the maximum tolerated 
dose of  twice-weekly  gemcitabine was 40 mg/m2 with 50 Gy 
radiation and conventional radiation fields. The Cancer and 
Leukemia Group B25 performed a confirmatory Phase II 
trial of gemcitabine 40 mg/m2 twice weekly, with 50.4 Gy 
concurrent radiation in locally advanced pancreatic cancer, 
and found a median survival of 8.2 months. Small bowel and 
stomach toxicities reduced the maximum tolerated dose that 
could be achieved with gemcitabine and radiation, especially 
when relatively large radiation fields were used. Another 
approach has been reported by McGinn et al,26 who used 
full-dose gemcitabine (1000 mg/m2 weekly for 3 weeks), with 
radiation confined to the primary tumor. Among 33 patients 
with response-evaluable disease, ten (33%) experienced an 
objective response. The maximum tolerated dose was 36 Gy 
administered in 2.4 Gy fractions.
The combination of paclitaxel, gemcitabine, and exter-
nal irradiation has been evaluated in a Phase I study by 
Brown University Oncology Group (BrUOG), showing 
that the limiting toxicities were gastrointestinal side effects 
such as nausea, diarrhea, and resultant dehydration, pre-
sumably from small bowel toxicity.14 The level of toxicity 
of this combination with large radiation fields (averaging 
15 × 15 cm) explains the toxicity observed in our study, in 
which conventional radiation fields similar to those used 
in RTOG 98-12 were used. Based on these preliminary 
data, we chose to evaluate weekly gemcitabine at a dos-
age of 75 mg/m2 and a lower weekly paclitaxel  dosage of 
40 mg/m2 (20% below that used in RTOG 98-12), since 
the Phase I study suggested they could be logistically 
incorporated, with acceptable toxicity, into a multicenter 
treatment protocol.
Our data demonstrate that a dual radiation sensitizer 
combination produces a median survival of 1-year and 
a 1-year survival rate of 50%. While these results were 
not significantly better than paclitaxel and concurrent 
radiation in RTOG 98-12, they provide further validation 
of the importance of chemoradiation in locally advanced 
pancreatic cancer. Using only locoregional treatment, 
without systemic dosages of gemcitabine, a median 1-year 
survival of approximately 50% was achieved. In future, 
one could consider the use of higher radiation doses 
accompanied by single or multiple radiation sensitizers, 
especially now that highly conformal treatment can be 
Figure 3 Treatment schema (online).
Abbreviations: R115777, farnesyl transferase inhibitor; po bid, taken orally twice a day; CT, computed tomographic; MRI, magnetic resonance imaging.
S Tumor dimension R Arm 1
1. ,5 cm Radiation therapy: 50.4 Gy (1.8 Gy × 28 fractions)
T 2. .5 cm A Paclitaxel: 40 mg/m2/week by 1-hour iv infusion on days 1, 8, 15, 22, 29, 36
R Weight loss N Gemcitabine: 75 mg/m2/week on days 1, 8, 15, 22, 29, 36
1. #10% body weight
A 2. .10% body weight D Arm 2
Radiation therapy: 50.4 Gy (1.8 Gy × 28 fractions)
T O Paclitaxel: 40 mg/m2/week by 1-hour iv infusion on days 1, 8, 15, 22, 29, 36
I M Gemcitabine: 75 mg/m2/week on days 1, 8, 15, 22, 29, 36
R115777: 300 mg po bid for 21 days every 28 days, to start 3–8 weeks
F I after the last radiation treatment and continue until disease progression or 
unacceptable toxicity.
Y Z
Two to three weeks following completion of chemoradiotherapy,
E all patients will be restaged by CT/MRI scan. Patients without disease
progression who are randomized to Arm 2 will begin R115777 3–8 weeks 
after completion of chemoradiotherapy.
Day (Arms 1 and 2) Day (Arm 2)
Radiation 1→5 8→12 15→19 22→26 29→33 36→38
59 (up to day 94) start R115777 and continue 
until progression or unacceptable toxicity
Paclitaxel 1 8 15 22 29 36
Gemcitabine 1 8 15 22 29 36
R115777
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Table 4 Chemotherapy, inhibitor, and acute radiation toxicity
Category CXRT  
(n = 91) grade
CXRT+R115777  
(n = 94) grade
1 2 3 4 5 1 2 3 4 5
Allergy/immunology 1 0 3 0 0 1 0 2 0 0
Auditory/hearing 0 0 0 0 0 1 1 0 0 0
Blood/bone marrow 21 30 26 4 0 13 30 32 11 0
Cardiovascular (arrhythmia) 0 0 0 0 0 1 1 0 0 0
Cardiovascular (general) 4 8 2 1 0 7 4 7 0 0
Coagulation 0 0 1 0 0 1 1 0 0 0
Constitutional symptoms 25 29 8 0 0 23 33 13 1 0
Dermatology/skin 12 5 0 0 0 13 6 0 0 0
Endocrine 0 1 1 0 0 0 0 0 0 0
Gastrointestinal 18 30 30 2 0 9 37 33 4 0
Hemorrhage 2 0 0 0 0 4 0 1 1 0
Hepatic 14 12 3 0 0 17 22 10 2 0
Infection febrile neutropenia 0 3 5 0 0 0 7 8 0 0
Metabolic/laboratory 25 13 5 0 0 16 15 15 1 0
Musculoskeletal 0 0 0 0 0 0 0 2 0 0
Neurology 13 6 1 0 0 17 16 7 1 0
Ocular/visual 0 0 0 0 0 1 2 0 0 0
Pain 12 18 6 1 0 14 20 7 0 0
Pulmonary 4 5 1 0 0 1 9 1 1 0
Renal/genitourinary 6 0 0 0 0 11 2 0 0 0
Sexual/reproductive function 0 0 1 0 0 1 0 0 0 0
Worst nonhematologic 16 
(17.6%)
24 
(26.4%)
45 
(49.5%)
4 
(4.4%)
0 
(0%)
4 
(4.3%)
24 
(25.5%)
52 
(55.3%)
7 
(7.4%)
0 
(0%)
Worst GI and pulmonary 18 
(19.8%)
30 
(33.0%)
31 
(34.1%)
2 
(2.2%)
0 
(0%)
8 
(8.5%)
36 
(38.3%)
33 
(35.1%)
5 
(5.3%)
0 
(0%)
Worst overall 5 
(5.5%)
25 
(27.5%)
54 
(59.3%)
7 
(7.7%)
0 
(0%)
3 
(3.2%)
16 
(17.0%)
54 
(57.4%)
17 
(18.1%)
0 
(0%)
Note: Toxicities were graded with CTC version 2.0.
Abbreviations: CTC, common toxicity criteria; CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; GI, gastrointestinal.
Table 5 Late radiotherapy toxicity (online)
CXRT 
(n = 80) grade
CXRT+R115777 
(n = 78) grade
1 2 3 4 5 1 2 3 4 5
Small/large intestine 2 3 0 0 0 4 0 1 0 0
Skin 1 0 0 0 0 0 0 0 0 0
Subcutaneous tissue 1 0 0 0 0 0 0 0 0 0
Other 2 0 4 0 0 0 1 2 0 0
Worst late toxicity 5 
(6.3%)
2 
(2.5%)
4 
(5%)
0 
(0%)
0 
(0%)
3 
(3.8%)
1 
(1.3%)
2 
(2.6%)
0 
(0%)
0 
(0%)
Note: Toxicities were graded with RTOG/EORTC late toxicity criteria.
Abbreviations: CXRT, concurrent radiation with gemcitabine and paclitaxel; R115777, farnesyl transferase inhibitor; EORTC, European Organization for Research and 
Treatment of Cancer; RTOG, Radiation Therapy Oncology Group.
delivered to well-defined tumor volumes, to determine 
benefit.
R115777 following chemoradiation was not effective 
and may have been harmful. Farnesyl transferase inhibitors 
have been developed to alter the activity of ras oncogenes 
and the proteins they encode, which are commonly found 
in pancreatic cancer, making inhibition of ras a rational 
target. R115777 has been shown in several preclinical 
tests to inhibit H-ras, K-ras, and N-ras activity in trans-
formed tumors.27 Since the original design of RTOG 0020, 
results from two Phase II studies and a Phase III study 
failed to show single-agent activity for R115777. In a 
Southwest Oncology Group study (9924),28 48 previously 
untreated patients with metastatic and locally advanced 
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pancreatic cancer were treated with R115777 (300 mg 
orally twice daily × 21 days of a 28-day cycle). The median 
survival was 3 months, with a time to treatment failure 
of 1 month. A Belgian study of R115777 for metastatic 
disease patients29 showed pharmacodynamic data dem-
onstrating that the drug did indeed successfully inhibit 
farnesyl transferase activity and suppress farnesylation 
of a target protein in peripheral blood mononuclear cells. 
This confirmed mechanism of action did not translate 
into clinical efficacy, since no objective responses were 
observed, the median survival was 19.7 weeks, and the 
6-month survival rate was 25%. A Phase III study of 688 
patients with pancreatic cancer comparing gemcitabine 
to the combination of gemcitabine and R115777 did not 
demonstrate an improvement in outcome.30
Hematologic toxicity from R115777 has been reported 
in prior studies. The occurrences of neurologic, hepatic, 
musculoskeletal, cardiac, and metabolic toxicities were not 
appreciated in prior studies. Some of these toxicities may 
have been due to disease progression including edema (clas-
sified as a cardiac toxicity), hyperglycemia, and hypoalbu-
minemia. However, the elevation of hepatic transaminases 
in the absence of hyperbilirubinemia and the neurologic 
and musculoskeletal adverse events may have been due to 
the broad range of pathway inhibition by R115777. The 
appearance and recognition of these toxicities in RTOG 
0020, as compared to other studies, may have been due to the 
effectiveness of the chemoradiation regimen, so that patients 
remained on R115777 for an extended period of time. The 
median treatment time was only 77 days in the Phase III 
study of R115777 in advanced colon cancer. In addition 
to the Ras family of proteins, R115777 inhibits farnesyl 
 transferase in Rho-B and Rho-E, protein tyrosine phos-
phatase 4A (PTP4A)-1 and PTP4A-2, centromere-associated 
protein (CENP)-E and CENP-F, and lamins. This nonselec-
tivity inhibiting multiple pathways may have contributed to 
the toxicities associated with R115777 maintenance.
In summary, the RTOG trial 0020 failed to demonstrate 
that the addition of a second radiation sensitizer, weekly 
gemcitabine, significantly improves survival for patients 
with locally advanced pancreatic cancer, as compared to 
RTOG 98-12. However, the 1-year survival of approximately 
50% is encouraging and reaffirms the role of chemoradia-
tion in locally advanced pancreatic cancer. In the future, 
more effective systemic agents, either chemotherapeutic 
or biologic, will be combined with chemoradiation to 
optimize locoregional and systemic control to ultimately 
improve survival.
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